Impraz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the effective management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine antagonist, facilitates gastric motility by enhancing the movement of stomach contents into the intestines, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), acts by selectively inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. The combination of these two agents provides both symptomatic relief and promotes mucosal healing by addressing acid overproduction and improving gastric emptying. Impraz-DSR is indicated for patients experiencing frequent heartburn, erosive esophagitis, and other acid-related disorders where both acid suppression and prokinetic effects are beneficial. It is recommended to be taken as prescribed by a healthcare professional, typically before meals, to optimize therapeutic outcomes. Caution is advised in patients with known hypersensitivity to either component, and it should be used with care in those with underlying cardiac conditions or hepatic impairment. Regular monitoring and adherence to prescribed dosage enhance safety and efficacy.